# Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

> **NCT01341782** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 255 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- Hemodialysis

## Interventions

- **DRUG:** paricalcitol
- **DRUG:** maxacalcitol
- **DRUG:** paricalcitol placebo
- **DRUG:** maxacalcitol placebo

## Key facts

- **NCT ID:** NCT01341782
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2013-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01341782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01341782, "Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01341782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*